The cost pressures of Divis Labs are easing across major factors, indicating improved profitability going forward. The outlook for contrast media segment remains encouraging, given DIVI’s capability to have better Iodine recovery and limited investment by formulators to manufacture API. The green-field capital expenditure at Kakinada would not only cater to the company’s growth requirements […]
